Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022, 166(3):312-321 | DOI: 10.5507/bp.2022.020

The prognosis and therapeutic management of patients hospitalized for heart failure in 2010-2020

Otto Mayer Jra, b, Jan Bruthansa, c, Simona Bilkovaa, b, Jitka Seidlerovaa, b, Josef Jirakd, Jan Filipovskya, b
a 2nd Department of Internal Medicine, Faculty of Medicine, Charles University and University Hospital, Pilsen, Czech Republic
b Biomedical Center, Faculty of Medicine, Charles University Pilsen, Czech Republic
c Centre for Cardiovascular Prevention, First Faculty of Medicine, Charles, University and Thomayer's Hospital, Prague, Czech Republic
d Department of Informatics, University Hospital Pilsen, Czech Republic

Aims: We analyzed the mortality risk and its predictors in patients hospitalized for heart failure (HF).

Methods: Patients discharged from hospitalization for acute decompensation of HF in 2010-2020 and younger than 86 years were followed (n=4097). We assessed the incidence and trends of all-cause death, its main predictors, and the pharmacotherapy recommended at discharge from the hospital.

Results: The 30 days all-cause mortality was in discharged patients 3.2%, while 1-year 20.4% and 5-years 55.4%. We observed a modest trend to decreased 1-year mortality risk over time. Any increase of year of hospitalization by one was associated with about 5% lower risk in the fully adjusted model. Regarding predictors of 1-year mortality risk, a positive association was found for age over 65, history of malignancy, and peak brain natriuretic peptide during hospitalization ≥10times higher than normal concentration. In contrast, as protective factors, we identified LDL ≥1.8 mmol/L, treatment with beta-blockers, renin-angiotensin axis blockers, statins, and implanted cardioverter in the same regression model. The ejection fraction category and primary etiology of HF (coronary artery disease vs. others) did not significantly affect the mortality risk in a fully adjusted model.

Conclusions: Despite advances in cardiovascular disease management over the last two decades, the prognosis of patients hospitalized for heart failure remained highly unfavorable.

Keywords: cardiac decompensation, hospitalization, mortality risk, pharmacotherapy

Received: December 29, 2021; Revised: February 25, 2022; Accepted: April 6, 2022; Prepublished online: April 20, 2022; Published: September 14, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mayer, O., Bruthans, J., Bilkova, S., Seidlerova, J., Jirak, J., & Filipovsky, J. (2022). The prognosis and therapeutic management of patients hospitalized for heart failure in 2010-2020. Biomedical papers166(3), 312-321. doi: 10.5507/bp.2022.020
Download citation

References

  1. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Michael Felker G, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021;23(3):352-80. Go to original source... Go to PubMed...
  2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599-726. Go to original source... Go to PubMed...
  3. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604-12. Go to original source... Go to PubMed...
  4. Mayer O, Jr., Seidlerová J, Bruthans J, Opatrný J, Hromádka M, Jirák J, Filipovský J. The prognostic impact of renal function decline during hospitalization for myocardial infarction. J Comp Eff Res 2021; 10(3):219-28. Go to original source... Go to PubMed...
  5. Ohlmeier C, Mikolajczyk R, Frick J, Prütz F, Haverkamp W, Garbe E. Incidence, prevalence and 1-year all-cause mortality of heart failure in Germany: a study based on electronic healthcare data of more than six million persons. Clin Res Cardiol 2015;104(8):688-96. Go to original source... Go to PubMed...
  6. Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001. Heart 2003;89(6):615-20. Go to original source... Go to PubMed...
  7. Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002;162(15):1689-94. Go to original source... Go to PubMed...
  8. MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, Redpath A, Pell JP, McMurray JJ. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000;102(10):1126-31. Go to original source... Go to PubMed...
  9. Lin AH, Chin JC, Sicignano NM, Evans AM. Repeat Hospitalizations Predict Mortality in Patients With Heart Failure. Mil Med 2017;182(9):e1932-e1937. Go to original source... Go to PubMed...
  10. Mayer O, Jr., Rosolová H, Sefrna F, Neumann M, Simon J. [Analysis of mortality trends in the West Bohemian Region in comparison with the entire Czech Republic 1988-1995]. Cas Lek Cesk 1998;137(7):207-10. Go to PubMed...
  11. Bruthans J, Cífková R, Lánská V, O'Flaherty M, Critchley JA, Holub J, Janský P, Zvárová J, Capewell S. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. Eur J Prev Cardiol 2014;21(7):829-39. Go to original source... Go to PubMed...
  12. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev 2017;3(1):7-11. Go to original source... Go to PubMed...
  13. Buchan TA, Ching C, Foroutan F, Malik A, Daza JF, Hing NNF, Siemieniuk R, Evaniew N, Orchanian-Cheff A, Ross HJ, Guyatt G, Alba AC. Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis. 2022;27(2):645-54. doi: 10.1007/s10741-021-10136-3 Go to original source... Go to PubMed...
  14. Kagiyama N, Kitai T, Hayashida A, Yamaguchi T, Okumura T, Kida K, Mizuno A, Oishi S, Inuzuka Y, Akiyama E, Suzuki S, Yamamoto M, Shimizu A, Urakami Y, Toki M, Aritaka S, Matsumoto K, Nagano N, Yamamoto K, Matsue Y. Prognostic Value of BNP Reduction During Hospitalization in Patients With Acute Heart Failure. J Card Fail 2019;25(9):712-21. Go to original source... Go to PubMed...
  15. Khan MS, Fonarow GC, Khan H, Greene SJ, Anker SD, Gheorghiade M, Butler J. Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail 2017;4(4):402-8. Go to original source... Go to PubMed...
  16. Xie W, Zheng F, Song X, Zhong B, Yan L. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis. Int J Cardiol 2016;205:65-71. Go to original source... Go to PubMed...
  17. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353(9146):9-13. Go to original source...
  18. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106(17):2194-9. Go to original source... Go to PubMed...
  19. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353(9169):2001-7.
  20. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26(3):215-25. Go to original source... Go to PubMed...
  21. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709-17. Go to original source... Go to PubMed...
  22. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364(1):11-21. Go to original source... Go to PubMed...
  23. Pitt B, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail 2015;17(2):224-32. Go to original source... Go to PubMed...
  24. Afsarmanesh N, Horwich TB, Fonarow GC. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J 2006;152(6):1077-83. Go to original source... Go to PubMed...
  25. Weiss A, Beloosesky Y, Schmilovitz-Weiss H, Grossman E, Boaz M. Serum total cholesterol: a mortality predictor in elderly hospitalized patients. Clin Nutr 2013;32(4):533-7. Go to original source... Go to PubMed...
  26. Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M; EVEREST Trial Investigators. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol 2013;111(4):574-81. Go to original source... Go to PubMed...
  27. Horwich TB, Hernandez AF, Dai D, Yancy CW, Fonarow GC. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J 2008;156(6):1170-6. Go to original source... Go to PubMed...
  28. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 2007;93(8):914-21. Go to original source... Go to PubMed...
  29. Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385(9976):1397-405. Go to original source... Go to PubMed...
  30. Rogers JK, Jhund PS, Perez AC, Böhm M, Cleland JG, Gullestad L, Kjekshus J, van Veldhuisen DJ, Wikstrand J, Wedel H, McMurray JJV, Pocock SJ. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail 2014;2(3):289-97. Go to original source... Go to PubMed...
  31. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9645):1231-9. Go to original source... Go to PubMed...
  32. Zhang S, Zhang L, Sun A, Jiang H, Qian J, Ge J. Efficacy of statin therapy in chronic systolic cardiac insufficiency: a meta-analysis. Eur J Intern Med 2011;22(5):478-84. Go to original source... Go to PubMed...
  33. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators . Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352(3):225-37. Go to original source... Go to PubMed...
  34. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346(12):877-83. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.